BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
NYSE:BIO • US0905722072
264.93 USD
+8.37 (+3.26%)
Last: Feb 17, 2026, 08:04 PM
BIO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. BIO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- BIO had positive earnings in the past year.
- In the past year BIO had a positive cash flow from operations.
- BIO had negative earnings in 4 of the past 5 years.
- Of the past 5 years BIO 4 years had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of BIO (-6.97%) is comparable to the rest of the industry.
- With a Return On Equity value of -10.03%, BIO perfoms like the industry average, outperforming 53.45% of the companies in the same industry.
- BIO has a better Return On Invested Capital (2.26%) than 63.79% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BIO is significantly below the industry average of 12.04%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
- BIO has a Operating Margin of 10.27%. This is in the better half of the industry: BIO outperforms 70.69% of its industry peers.
- BIO's Operating Margin has been stable in the last couple of years.
- BIO has a better Gross Margin (52.42%) than 63.79% of its industry peers.
- In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
- BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- BIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- BIO has an Altman-Z score of 3.12. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of BIO (3.12) is better than 72.41% of its industry peers.
- The Debt to FCF ratio of BIO is 3.57, which is a good value as it means it would take BIO, 3.57 years of fcf income to pay off all of its debts.
- BIO's Debt to FCF ratio of 3.57 is fine compared to the rest of the industry. BIO outperforms 77.59% of its industry peers.
- A Debt/Equity ratio of 0.18 indicates that BIO is not too dependend on debt financing.
- BIO has a Debt to Equity ratio (0.18) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.12 |
ROIC/WACC0.22
WACC10.48%
2.3 Liquidity
- BIO has a Current Ratio of 5.44. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Current ratio value of 5.44, BIO belongs to the best of the industry, outperforming 86.21% of the companies in the same industry.
- A Quick Ratio of 3.94 indicates that BIO has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 3.94, BIO is in the better half of the industry, outperforming 68.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
- The earnings per share for BIO have decreased by -3.78% in the last year.
- The Earnings Per Share has been decreasing by -1.19% on average over the past years.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.85%
3.2 Future
- BIO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.38% yearly.
- The Revenue is expected to grow by 1.60% on average over the next years.
EPS Next Y3.33%
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
EPS Next 5Y-2.38%
Revenue Next Year1.61%
Revenue Next 2Y2.36%
Revenue Next 3Y2.35%
Revenue Next 5Y1.6%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 26.71, the valuation of BIO can be described as expensive.
- Based on the Price/Earnings ratio, BIO is valued a bit cheaper than 68.97% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.16, BIO is valued at the same level.
- BIO is valuated quite expensively with a Price/Forward Earnings ratio of 25.85.
- Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than 72.41% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of BIO to the average of the S&P500 Index (28.10), we can say BIO is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.71 | ||
| Fwd PE | 25.85 |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, BIO is valued cheaply inside the industry as 82.76% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.22 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIO does not grow enough to justify the current Price/Earnings ratio.
- A cheap valuation may be justified as BIO's earnings are expected to decrease with -3.38% in the coming years.
PEG (NY)8.01
PEG (5Y)N/A
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
5. Dividend
5.1 Amount
- BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:BIO (2/17/2026, 8:04:00 PM)
264.93
+8.37 (+3.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12 2026-02-12/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners92.92%
Inst Owner Change1.78%
Ins Owners8.18%
Ins Owner Change0%
Market Cap7.15B
Revenue(TTM)N/A
Net Income(TTM)-675.90M
Analysts76
Price Target362.1 (36.68%)
Short Float %4.47%
Short Ratio3.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)0%
PT rev (3m)14.15%
EPS NQ rev (1m)-1.46%
EPS NQ rev (3m)-4.14%
EPS NY rev (1m)-0.3%
EPS NY rev (3m)-0.9%
Revenue NQ rev (1m)-0.65%
Revenue NQ rev (3m)-1.79%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)-0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.71 | ||
| Fwd PE | 25.85 | ||
| P/S | 2.79 | ||
| P/FCF | 21.22 | ||
| P/OCF | 14.54 | ||
| P/B | 1.06 | ||
| P/tB | 1.24 | ||
| EV/EBITDA | N/A |
EPS(TTM)9.92
EY3.74%
EPS(NY)10.25
Fwd EY3.87%
FCF(TTM)12.48
FCFY4.71%
OCF(TTM)18.22
OCFY6.88%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)8.01
PEG (5Y)N/A
Graham Number236.12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.12 |
F-Score5
WACC10.48%
ROIC/WACC0.22
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y3.33%
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
EPS Next 5Y-2.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.85%
Revenue Next Year1.61%
Revenue Next 2Y2.36%
Revenue Next 3Y2.35%
Revenue Next 5Y1.6%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.36%
EBIT Next 3Y14.58%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
Can you provide the valuation status for BIO-RAD LABORATORIES-A?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for BIO stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to grow by 3.33% in the next year.